Key result
Indirect cascade screening for familial hypercholesterolemia faces key barriers including lack of educational resources and primary care awareness, based on qualitative interviews with 10 parents.
Answers are grounded in this paper and cite their sources.
Identifying family-reported barriers and facilitators to indirect cascade screening for familial hypercholesterolemia highlights the need for improved educational resources, primary care awareness, and access to pediatric lipid specialists.
Atherosclerosis, the pathobiological basis for cardiovascular disease (CVD), is a lifelong process and is linked with cardiovascular risk factors, including dyslipidemia.1Berenson G.S. Srinivasan S.R. Bao W. Newman 3rd, W.P. Tracy R.E. Wattigney W.A. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study.N Engl J Med. 1998; 338: 1650-1656https://doi.org/10.1056/NEJM199806043382302Crossref PubMed Scopus (3160) Google Scholar Given its often clinically silent nature in childhood, pediatric dyslipidemia can be easily missed. For example, familial hypercholesterolemia (FH), the most common inherited lipid disorder, present in its heterozygous form in ∼1:250-300 people, remains profoundly underdiagnosed.2Brunham L.R. Ruel I. Aljenedil S. Riviere J.B. Baass A. Tu J.V. Mancini G.B.J. Raggi P. Gupta M. Couture P. et al.Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018.Can J Cardiol. 2018; 34: 1553-1563https://doi.org/10.1016/j.cjca.2018.09.005Abstract Full Text Full Text PDF PubMed Scopus (73) Google Scholar This is particularly unfortunate for two key reasons: a clinical diagnosis is easily achieved via a screening lipid panel (demonstrating markedly elevated low-density lipoprotein cholesterol (LDL-C))3Ruel I. Brisson D. Aljenedil S. Awan Z. Baass A. Belanger A. Bergeron J. Bewick D. Brophy J.M. Brunham L.R. et al.Simplified Canadian Definition for Familial Hypercholesterolemia.Can J Cardiol. 2018; 34: 1210-1214https://doi.org/10.1016/j.cjca.2018.05.015Abstract Full Text Full Text PDF PubMed Scopus (48) Google Scholar and established treatments (namely statin therapy) exist that effectively lower LDL-C levels, reduce atherosclerotic burden, and potentially normalize CVD risk.4Luirink I.K. Wiegman A. Kusters D.M. Hof M.H. Groothoff J.W. de Groot E. Kastelein J.J.P. Hutten B.A. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia.N Engl J Med. 2019; 381: 1547-1556https://doi.org/10.1056/NEJMoa1816454Crossref PubMed Scopus (273) Google Scholar Thus, the effective detection and management of FH early in life is imperative, and should be considered a public health priority. Numerous screening strategies have been proposed to detect FH (Figure). Traditionally, selective screening on the basis of an identified family history of dyslipidemia or premature CVD was proposed. This approach, however, is insufficient, as screening on the basis of family history alone may miss 30-60% of cases, in part due to incomplete or unknown family histories.5Wiegman A. Gidding S.S. Watts G.F. Chapman M.J. Ginsberg H.N. Cuchel M. Ose L. Averna M. Boileau C. Boren J. et al.Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.Eur Heart J. 2015; 36: 2425-2437https://doi.org/10.1093/eurheartj/ehv157Crossref PubMed Scopus (534) Google Scholar, 6Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report.Pediatrics. 2011; 128: S213-256https://doi.org/10.1542/peds.2009-2107CCrossref PubMed Scopus (1888) Google Scholar, 7Wald D.S. Bestwick J.P. Reaching detection targets in familial hypercholesterolaemia: Comparison of identification strategies.Atherosclerosis. 2020; 293: 57-61https://doi.org/10.1016/j.atherosclerosis.2019.11.028Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar Universal screening is a preferred method for detecting index cases,6Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report.Pediatrics. 2011; 128: S213-256https://doi.org/10.1542/peds.2009-2107CCrossref PubMed Scopus (1888) Google Scholar,8Khoury M. Bigras J.L. Cummings E.A. Harris K.C. Hegele R.A. Henderson M. Morrison K.M. St-Pierre J. Wong P.D. McCrindle B.W. The Detection, Evaluation, and Management of Dyslipidemia in Children and Adolescents: A Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association Clinical Practice Update.Can J Cardiol. 2022; 38: 1168-1179https://doi.org/10.1016/j.cjca.2022.05.002Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar and has been proven to be an effective and economical strategy for FH detection, particularly when combined with a cascade screening strategy.9McKay A.J. Hogan H. Humphries S.E. Marks D. Ray K.K. Miners A. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.Atherosclerosis. 2018; 275: 434-443https://doi.org/10.1016/j.atherosclerosis.2018.05.047Abstract Full Text Full Text PDF PubMed Scopus (33) Google Scholar,10Wald D.S. Bestwick J.P. Morris J.K. Whyte K. Jenkins L. Wald N.J. Child-Parent Familial Hypercholesterolemia Screening in Primary Care.N Engl J Med. 2016; 375: 1628-1637https://doi.org/10.1056/NEJMoa1602777Crossref PubMed Scopus (206) Google Scholar Cascade screening involves the testing of first-degree family members of an index case with FH. Within the pediatric context, cascade screening is particularly important, as the child is often the first member of a family to be diagnosed (through selective or universal screening). Given the autosomal dominant nature of the disease, diagnosing FH in the child often permits the detection of severe dyslipidemia in one of the parents (i.e. reverse cascade screening), allowing for treatment prior to the development of premature CVD. For example, Wald et al., through a primary care screening program in the United Kingdom identified 40 children and 40 corresponding parents who screened positive for FH.10Wald D.S. Bestwick J.P. Morris J.K. Whyte K. Jenkins L. Wald N.J. Child-Parent Familial Hypercholesterolemia Screening in Primary Care.N Engl J Med. 2016; 375: 1628-1637https://doi.org/10.1056/NEJMoa1602777Crossref PubMed Scopus (206) Google Scholar With each new case identified, cascade screening can be stretched further to identify additional cases. This has proven to be highly effective for FH detection in multiple parts of the world, including in the Netherlands, for example, where about 70% of FH cases are estimated to have been identified.11Nordestgaard B.G. Chapman M.J. Humphries S.E. Ginsberg H.N. Masana L. Descamps O.S. Wiklund O. Hegele R.A. Raal F.J. Defesche J.C. et al.Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.Eur Heart J. 2013; 34: 3478-3490ahttps://doi.org/10.1093/eurheartj/eht273Crossref PubMed Scopus (1862) Google Scholar However, many such successful programs depend on direct contact from a health care practitioner to first-degree family members, termed direct cascade screening. This is not permissible in Canada, due to privacy laws. Thus, indirect cascade screening must be employed, where the patient/family is responsible for reaching out to family members themselves to recommend screening. Having buy-in from families affected by FH is essential to properly realize the potential of cascade screening. Namely, the family of each index case must understand the rationale for screening, the genetic basis for FH, and the implications of missed versus identified cases. Moreover, important factors such as cultural considerations and feelings of guilt or shame must be considered. Thus, an understanding of the knowledge and barriers among families surrounding cascade screening are needed to promote its uptake. Currently, these factors remain poorly understood, particularly within the Canadian context. In this issue of CJC Pediatric and Congenital Heart Disease, Dickson et al. undertook a qualitative study design using a Theoretical Domains Framework to detect facilitators and barriers in families with FH that may influence cascade screening efforts.12Dickson M.A. Zahavich L. Rush J. Hewson S. Chitayat D. McCrindle B.W. Chahal N. Exploring barriers and facilitators to indirect cascade screening for familial hypercholesterolemia in a pediatric/parent population.CJC Pediatric and Congenital Heart Disease. 2023; (In Press)https://doi.org/10.1016/j.cjcpc.2023.05.006Abstract Full Text Full Text PDF Google Scholar Parents of children with a clinical diagnosis of FH were recruited from the pediatric lipid subspecialty clinic at the Hospital for Sick Children in Toronto, Canada. Saturation was achieved after 10 interviews, and 9/10 parents interviewed had a self-reported diagnosis of FH. Through the Theoretical Domains Framework, four key facilitators were identified: surprise that children are susceptible to FH, knowledge gained through participation in the lipid clinic, the importance of access to trusted specialists, and a sense of responsibility to protect family members from CVD. In addition, four key barriers were identified: lack of educational resources to facilitate giving information to family members and generating public awareness, a lack of primary care practitioner (PCP) awareness with respect to the diagnosis and treatment options in children, a desire to protect the children’s health status to avoid stigma, and the dismissal of the seriousness of FH by relatives. It is important to note that the implementation of a direct cascade screening program would address a key identified barrier, namely the lack of resources available for patients/families to notify and inform their first-degree family members. Despite this, the authors emphasize that the subspeciality clinic educated and empowered families, which in turn helped them understand the importance of cascade screening. While this is promising, it highlights the possibility for discrepancies in patient knowledge and empowerment as a result of access to care, including subspecialty pediatric lipid clinics, of which there are relatively few in Canada. Supporting this, parents in the present study also identified resistance from PCPs regarding FH screening and treatment with statins in children with FH. Prior work supports this perceived barrier. For example, in a survey administered through the Canadian Paediatric Surveillance Program, only 3% of primary-care providing pediatricians indicated that they perform lipid screening in healthy children “most/all of the time.”13Khoury M. Rodday A.M. Mackie A.S. Gill P. McLaughlin T. Harris K.C. Wong P. McCrindle B.W. Birken C.S. de Ferranti S.D. Pediatric Lipid Screening and Treatment in Canada: Practices, Attitudes, and Barriers.Can J Cardiol. 2020; 36: 1545-1549https://doi.org/10.1016/j.cjca.2020.05.035Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar Moreover, 24% disagreed or strongly disagreed with the notion that statins were appropriate for youth with severe dyslipidemia, despite increasingly robust evidence of their effectiveness and safety.14Khoury M. McCrindle B.W. The Rationale, Indications, Safety, and Use of Statins in the Pediatric Population.Can J Cardiol. 2020; 36: 1372-1383https://doi.org/10.1016/j.cjca.2020.03.041Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar,15Vuorio A. Kuoppala J. Kovanen P.T. Humphries S.E. Tonstad S. Wiegman A. Drogari E. Ramaswami U. Statins for children with familial hypercholesterolemia.The Cochrane database of systematic reviews. 2019; 2019https://doi.org/10.1002/14651858.CD006401.pub5Crossref PubMed Scopus (30) Google Scholar These findings, coupled with the identified facilitators and barriers in the present study emphasize the need for continued knowledge translation strategies to improve the uptake of pediatric FH screening and management among Canadian PCPs. In addition, improved access to pediatric subspecialty lipid clinics is needed. Novel strategies are needed to help accomplish this, including the leveraging of existing telemedicine technologies to expand geographic reach and facilitate improved access and convenience for families. Moreover, lipid clinics should position themselves as a centralized hub, whereby they are integrated with primary-care practices and the local community, providing clinical support and educational resources to enable PCPs and families alike. The theoretical framework of this study identified important insights and perceived facilitators and barriers for indirect cascade screening. However, certain limitations were inherent to the study design that must be considered. First, as the authors identify, this study consisted of 10 parents recruited from a dedicated pediatric lipid clinic in a large urban center, thus limiting the generalizability of the findings. Further limiting generalizability was the finding that 8/10 parents interviewed identified as white and 9/10 had received a college or university education, despite an effort to purposely sample and achieve maximal variation in the study population. Finally, there was a lack of emphasis on genetic testing through the interviews and in the study results. The authors indicate this is largely due to a lack of availability of routine genetic testing for FH in Ontario as part of standard care. Genetic testing is being increasingly recommended and utilized in FH diagnosis and cascade screening.8Khoury M. Bigras J.L. Cummings E.A. Harris K.C. Hegele R.A. Henderson M. Morrison K.M. St-Pierre J. Wong P.D. McCrindle B.W. The Detection, Evaluation, and Management of Dyslipidemia in Children and Adolescents: A Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association Clinical Practice Update.Can J Cardiol. 2022; 38: 1168-1179https://doi.org/10.1016/j.cjca.2022.05.002Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar,16Sturm A.C. Knowles J.W. Gidding S.S. Ahmad Z.S. Ahmed C.D. Ballantyne C.M. Baum S.J. Bourbon M. Carrie A. Cuchel M. et al.Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.J Am Coll Cardiol. 2018; 72: 662-680https://doi.org/10.1016/j.jacc.2018.05.044Crossref PubMed Scopus (282) Google Scholar The incorporation of genetic testing considerations may have uncovered unique perceived facilitators and barriers that are likely to become increasingly relevant across Canada in the years to come. For example, the parents identified perceived stigma as a significant barrier. This includes the stigma of having a chronic disease, but also the misperception that their child’s dyslipidemia is a result of an unhealthy lifestyle. Genetic testing may serve as a confirmation that the driving etiology at play is not improper dietary or lifestyle choices. Moreover, it may convey the seriousness of FH and the need for testing family members, while also improving the precision and sensitivity of cascade screening, as screening on the basis of a clinical diagnosis alone may is limited by incomplete penetrance in family members.16Sturm A.C. Knowles J.W. Gidding S.S. Ahmad Z.S. Ahmed C.D. Ballantyne C.M. Baum S.J. Bourbon M. Carrie A. Cuchel M. et al.Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.J Am Coll Cardiol. 2018; 72: 662-680https://doi.org/10.1016/j.jacc.2018.05.044Crossref PubMed Scopus (282) Google Scholar It is thus crucial for genetic testing for FH to be made accessible across Canada to facilitate prompt diagnosis and treatment. The impact of genetic testing on patient and parent attitudes towards FH cascade screening will require further study. So where do we go from here? The systematic detection of FH from childhood is crucial in order to reduce atherosclerotic burden and prevent premature CVD. Our patients and their families are uniquely positioned, existing both as individuals in need of treatment while also being tasked with the responsibility to disclose a diagnosis and explain and promote screening to their families. We must do all we can to facilitate this and support our patients. Dickson et al. have provided us with a useful framework by which to achieve this. Exploring Barriers and Facilitators to Indirect Cascade Screening for Familial Hypercholesteraemia in a Paediatric/Parent PopulationCJC Pediatric and Congenital Heart DiseasePreviewFamilial hypercholesteraemia (FH), an inherited disorder of cholesterol metabolism, has a prevalence of 1:250 and an associated 6- to 22-fold increased risk for cardiovascular disease. Despite the prevalence and availability of effective risk-reduction treatments, 90% of at-risk Canadians are undiagnosed. Indirect cascade screening from an index case is useful but the uptake is low (<4%), suggesting that barriers may exist. Using the Theoretical Domains Framework, we sought to determine barriers and facilitators among parents of children diagnosed with FH that may influence the uptake of cascade screening among families.
No takes yet. Share an insight, caveat, or question.
Michael Khoury (2023) conducted an editorial in Familial Hypercholesterolemia (n=10). Indirect cascade screening was evaluated on Facilitators and barriers to indirect cascade screening. Indirect cascade screening for familial hypercholesterolemia faces key barriers including lack of educational resources and primary care awareness, based on qualitative interviews with 10 parents.
Synapse has enriched 10 related papers. Consider them for comparative context: